Filed a patent application for ANL301, a therapeutic agent for Lafora disease

- Filed a patent applicaion for INSIGHTMINER, an AI-driven AAV Engineering platform
- aMCI biomarker patent application
- Made a presentation of an AAV program at ISCT 2023 in Paris (Collaborative research with Samsung Seoul Hospital)

Signed MOUs with Kyungdong Pharmaceutical Co., Ltd. for GMP CDMO and L/O

- Signed Research and Development Agreement with ToolGen
- Inno-Biz Certification (Minister of Small and Medium Venture Business)

Series A fundraising

Signed CDMO contract with BIOVIAN

Signed a MOU with MedySapiens

ANL-105 domestic patent registration

ANL-104 domestic patent registered

- Won an award of Technology Commercializtion, Ministry of Health and Welfare, South Korea
- Designated as a preclinical dementia study by a governmental agency of dementia R&D

Certification of venture companies
ANL-101 patent registered in the US

ANL-104/105 transfer

Certification of corporate research institutes

ANL-101 transfer completed

Corporate Established

ANL-104 filed in Korea

- ANL-101 registered in Korea
- ANL-105 filed in Korea

ANL-101 (Alzheimer) patent filed

Filed in Republic of Korea
Filed in US and CHINA (including PCT)

Underlying technology - Mainly studied by Dr.Keetae Kim, the co-founder

- Joint research by IBS and DGIST
- Originally studied the relationship between aging and MicroRNA